CSTK - ETF AI Analysis

Top Page

Invesco Comstock Contrarian Equity ETF (CSTK)

Rating:72Outperform

Price Target:―

CSTK, the Invesco Comstock Contrarian Equity ETF, earns a solid overall rating driven by high-quality leaders like Alphabet (GOOGL), Merck (MRK), and Johnson & Johnson (JNJ), which benefit from strong financial performance, positive earnings calls, and attractive long-term growth drivers such as AI, healthcare innovation, and strategic initiatives. Additional support comes from financially sound names like Cisco (CSCO), Wells Fargo (WFC), and State Street (STT), though weaker spots such as CVS Health (CVS), with profitability challenges, bearish technical trends, and legal-related headwinds, modestly weigh on the fund. The main risk factor is its meaningful exposure to a few large financial and healthcare names, which can increase sensitivity to sector-specific setbacks.

Positive Factors

Broad Sector Diversification

The fund spreads its investments across many sectors, which can help reduce the impact if any one industry struggles.

Mix of Defensive and Growth Companies

Top holdings include well-known health care, technology, and communication services companies that can provide a balance of stability and growth potential.

Moderate Expense Ratio

The fund’s fee level is reasonable for an actively managed equity ETF, allowing investors to keep more of their returns compared with higher-cost options.

Negative Factors

Heavy U.S. Market Focus

With almost all assets in U.S. stocks, the fund offers little geographic diversification and is highly tied to the U.S. market’s ups and downs.

Financial Sector Concentration

A large allocation to financial stocks, including several top holdings, means the fund could be hit hard if the financial sector weakens.

Several Lagging Top Holdings

Some of the largest positions, particularly in financials and technology, have shown weak recent performance, which can drag on overall returns.

CSTK vs. SPDR S&P 500 ETF (SPY)

AUM113.31M

RegionGlobal

Expense Ratio0.35%

Beta0.79

IssuerInvesco

Inception DateMay 07, 2025

Dividend YieldN/A

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume1,262

30 Day Avg. Volume3,486

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

33.58

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering53

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

CSTK Summary

The Invesco Comstock Contrarian Equity ETF (CSTK) is an actively managed fund that looks for undervalued stocks across the total U.S. market, with a value-focused, contrarian approach. It doesn’t track a set index, but instead picks companies the managers believe are priced below their true worth. The fund holds well-known names like Alphabet (Google) and Bank of America, and spreads investments across many sectors, which can help with diversification and potential long-term growth. A key risk is that these “out of favor” value stocks can stay unpopular for long periods, so the share price can go up and down more than you expect.

How much will it cost me?The Invesco Comstock Contrarian Equity ETF (CSTK) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it’s actively managed, which involves more research and decision-making compared to passively managed funds that track an index.

What would affect this ETF?The CSTK ETF could benefit from a global economic recovery, which may boost undervalued companies across sectors like financials, healthcare, and technology, where it has significant exposure. However, rising interest rates or regulatory changes in key sectors like financials and healthcare could negatively impact its holdings, while global economic uncertainty might weigh on its contrarian investment strategy. Its focus on undervalued companies provides potential for growth but also carries risks if market conditions remain unfavorable.

CSTK Top 10 Holdings

CSTK’s story is classic contrarian value: big U.S. financials like Bank of America and Wells Fargo are lagging, acting as a bit of a weight on returns even as management sees long-term upside. On the brighter side, health care heavyweights Merck and Johnson & Johnson are quietly pulling the fund forward with steady, rising performance. Chevron adds an energy kicker, recently climbing on solid cash generation and income appeal. With a global mandate but a clear tilt toward U.S. value names in financials, health care, and energy, this ETF is betting that today’s wallflowers become tomorrow’s leaders.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
GOOGL	Alphabet Class A	4.23%	$4.79M	$4.08T	65.67%	85 Outperform
BAC	Bank of America	3.89%	$4.40M	$388.49B	14.90%	72 Outperform
CVX	Chevron	3.48%	$3.94M	$356.19B	18.57%	71 Outperform
WFC	Wells Fargo	3.40%	$3.85M	$279.85B	14.84%	80 Outperform
MRK	Merck & Company	3.22%	$3.65M	$273.69B	11.59%	80 Outperform
CSCO	Cisco Systems	3.16%	$3.58M	$309.45B	29.24%	77 Outperform
STT	State Street	2.85%	$3.22M	$36.52B	28.77%	75 Outperform
CVS	CVS Health	2.78%	$3.15M	$94.60B	31.94%	64 Neutral
JNJ	Johnson & Johnson	2.69%	$3.04M	$547.51B	49.36%	78 Outperform
JCI	Johnson Controls	2.65%	$3.00M	$73.00B	52.90%	70 Outperform

CSTK Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

29.14

Positive

100DMA

28.46

Positive

200DMA

Market Momentum

MACD

0.23

Positive

RSI

60.38

Neutral

STOCH

75.38

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CSTK, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.84, equal to the 50-day MA of 29.14, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 60.38 is Neutral, neither overbought nor oversold. The STOCH value of 75.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CSTK.

CSTK Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
CSTK	―	―	$113.31M	0.35%	―
BKDV	―	―	$879.26M	0.60%	―
GMOI	―	―	$361.74M	0.60%	―
FPAG	―	―	$324.73M	0.49%	―
COPY	―	―	$247.62M	0.80%	―
MFSV	―	―	$247.49M	0.44%	―

Performance Comparison

CSTK

Invesco Comstock Contrarian Equity ETF

30.05

5.29

21.37%

BKDV

BNY Mellon Dynamic Value ETF

―

GMOI

GMO International Value ETF

―

FPAG

FPA Global Equity ETF

―

COPY

Tweedy Browne Insider + Value ETF Trust Units

―

MFSV

MFS Active Value ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents